Litcius/Paper detail

CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients’ Survival

Jing Xu, Laiming Wei, Hao Liu, Lei Yu, Yanzhe Zhu, Chang Yin Liang, Guoping Sun

2022Cancer Investigation19 citationsDOIOpen Access PDF

Abstract

This study was carried out to demonstrate the prognostic value of CD274 (PD-L1 promoter gene) methylation in bladder cancer patients. UCSC Xena database was searched for relevant information on PD-L1 (CD274) methylation and PD-L1 mRNA expression in bladder cancer. 407 bladder patients were included in our analyses. Multivariate analysis revealed that PD-L1 methylation was an independent predictor for OS (P = 0.037). Moreover, PD-L1 methylation might be a prognostic biomarker for immunotherapy response. However, PD-L1 methylation and PD-L1 mRNA expression was not statistically associated with chemotherapy response. In conclusion, PD-L1 methylation was an independent prognostic factor for bladder cancer patients.

Topics & Concepts

MethylationBladder cancerOncologyImmunotherapyMedicineBiomarkerCancerInternal medicineMultivariate analysisDNA methylationCancer researchGene expressionBiologyGeneBiochemistryBladder and Urothelial Cancer TreatmentsEpigenetics and DNA MethylationCancer Immunotherapy and Biomarkers
CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients’ Survival | Litcius